Heparin cryoprecipitation reduces plasma levels of non-traditional risk factors for atherosclerosis in vitro

Blood Purification

Volumn 26, Issue 3, 2008, Pages 238-248

  Meilin, E ^a,b   Sela, S ^a,b   Kristal, B ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Atherosclerosis; Heparin cryoprecipitation of plasma; Inflammation; Non traditional risk factors; Oxidized molecules

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; C REACTIVE PROTEIN; FIBRINOGEN; HEPARIN; INTERLEUKIN 6; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRECIPITATION; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PURIFICATION; REVIEW; RISK FACTOR;

ACUTE-PHASE PROTEINS; AGED; ATHEROSCLEROSIS; BLOOD PROTEINS; BLOOD SPECIMEN COLLECTION; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; FREEZING; GELS; HEPARIN; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PLASMA; PRECIPITATION; PROTEIN CARBONYLATION; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44349172986     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119543     Document Type: Review

References (38)

1. Muntner P, Hamm LL, Kusek JW, Chen J, et al: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004;140:9-17.
2. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al: Advanced oxidation protein products as risk factors for atherosclerosic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.
3. Siato I, Folsom AR, Brancati FL, Duncan BB, et al: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Ann Intern Med 2000;133:81-91.
4. Miyata T, Ueda Y, Yamada Y, et al: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;2349-2356.
5. Shacter E: Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000;32:307-326.
6. Nystrom T: Role of oxidative carbonylation in protein quality control and senescence. EMBO J 2005;24:1311-1317.
7. Munch G, Berbaum K, Urban C, et al: Proteins of Thermus thermophilus are resistant to glycation-induced protein precipitation: an evolutionary adaptation to life at extreme temperatures? Ann NY Acad Sci 2005;1043:865-875.
8. Luthra M, Balasubramanian D: Nonenzymatic glycation alters protein structure and stability. A study of two eye lens crystallins. J Biol Chem 1993;268:18119-18127.
9. Faucette KJ, Fitzgerald LA, Liu L, Parker CJ, Rodgers GM: Characterization of the interactions between procoagulant albumin and human endothelial cells. Blood 1993;82:2684-2692.
10. Anraku M, Yamasaki K, Maruyama T, et al: Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 2001;18:632-639.
11. Mera K, Anraku M, Kitamura K, et al: The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005;334:1332-1328.
12. Shacter E, Williams JA, Lim M, et al: Differential susceptibility of plasma proteins to oxidative modification: examination by Western blot immunoassay. Free Radic Biol Med 1994;17:429-437.
13. Azizova OA, Maksyanina EV, Romanov YA, Aseichev AV, Scheglovitova ON: Fibrinogen and its oxidized form induce interleukin-8 production in cultured endothelial cells in human vessels. Bull Exp Biol Med 2004;137:358-360.
14. Smith JW, Kayashima K, Katsume C, et al: Cryopheresis: immunochemical modulation and clinical response in autoimmune disease. Trans Am Soc Artif Intern Organs 1982;28:391-395.
15. Michelis R, Gery R, Sela S, et al: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003;18:924-930.
16. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
17. Siami GA, Siami FS: Current topics on cryofiltration technologies. Ther Apher 2001;5:283-286.
18. Nose Y, Horiuchi T, Malchesky PS, et al: Therapeutic cryogel removal in autoimmune disease: What is Cryogel? Ther Apher 2000;4:38-43.
19. Himmelfarb J, McMonagle E: Albumin is the major plasma protein target of oxidative stress in uremia. Kidney Int 2001;60:358-363.
20. Stenvinkel P, Ketteler M, Jonson RJ, et al: IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia - the good, the bad and the ugly. Kidney Int 2005;67:1216-1233.
21. Woods A, Brull DJ, Humphries SE, et al: Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000;21:1574-1583.
22. Duperray A, Languino LR, Plescia J, et al: Molecular Identification of a novel fibrinogen binding site on the first domain of ICAM-1-1 regulating leukocyte-endothelium bridging. J Biol Chem 1997;272:435-441.
23. Mitch WE: Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 2002;110:437-439.
24. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK; HEMO Study Group: Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am Kidney Dis 2002;40:721-727.
25. Oh DJ, Lee KJ: The relation between hypoalbuminemia and compliance and intima-media thickness of carotid artery in continuous ambulatory peritoneal dialysis patients. J Korean Med Sci 2005;20:70-74.
26. Danielski M, Ikizler TA, McMonagle E, et al: Linkage of hypoalbuminemia, inflammation and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003;42:286-294.
27. Kaysen A, Don BR: Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int 2003;63:94-97.
28. Volwiler W, Goldsworthy PD, MacMartin M, et al: Biosynthetic determination with radioactive sulfur of turnover rates of various plasma proteins in normal and cirrhotic man. J Clin Invest 1955;34:1126-1146.
29. Witko-Sarsat V, Friedlander M, Nguyen TN, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. Immunology 1998;161:2524-2532.
30. Skvarilova M, Bulava A, Stejskal D, et al: Increased levels of advanced oxidation products as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Papers 2005;149:83-87.
31. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis. Hypertension 2004;44:6-11.
32. Otto C, Geiss HC, Empen K, et al: Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis 2004;174:151-156.
33. Agrawal A: CRP after 2004. Mol Immunol 2005;42:927-930.
34. Yamagishi SI, Inagaki Y, Nakamura K, et al: Pigment epithelium-derived factor inhibits TNF-α induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004;37:497-506.
35. Harvima TI, Lappalainen K, Hirvonen MR, et al: Heparin modulates the growth and adherence and augments the growth-inhibitory action of TNF-α on cultured human keratinocytes. J Cell Biochem 2004;92:372-386.
36. Mellwig KP: Heparin-induced extracorporeal low density lipoprotein precipitation. Ther Apher Dial 2003;7:365-369.
37. Wang Y, Blessing F, Walli AK, et al: Effect of heparin-induced extracorporeal low density lipoprotein precipitation beyond lowering proatherogenetic lipoproteins - reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004;175:145-150.
38. Bolton CH, Downs LG, Jason GG, et al: Endothelial dysfunction in chronic renal failure: role of lipoprotein oxidation and proinflammatory cytokines. Nephrol Dial Transplant 2001;16:1189-1197.